ArticleIndian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2025
Arora-Nagarkar Prognostic Classification for Rhinocerebral Mucormycosis
Article in Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A Retroprospective observational study was conducted on Covid-19-associated mucormycosis (CAM) patients who underwent surgery at our institute. A total of 175 patients who met the inclusion and exclusion criteria were included in our study The study aimed to correlate the Overall survival and disease-specific survival rates with sites of involvement in patients with Covid Associated Mucormycosis and develop a novel prognostic classification of Mucormycosis. At the end of 24 months, the overall survival rate was 73.1% which can be attributed to the early diagnosis, timely & aggressive intervention, and multidisciplinary management. The Disease-Specific Survival rates were 90.16% (55alive/61total) for Sinonasal Mucormycosis, 87% (41/47) for Rhinomaxillary Mucormycosis, 64.7% (22/34) for Rhinoorbital Mucormycosis and 45.45% (10/22) for Rhinocerebral Mucormycosis. A statistically significant difference was seen between the disease severity and outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.